BridgeBio Pharma Inc

BBIO

68.050USD

+4.320+6.78%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

BridgeBio Pharma Inc's Score

Industry at a Glance

Industry Ranking

33 / 159

Overall Ranking

97 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

BridgeBio Pharma Inc Highlights

StrengthsRisks

BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 185.78% year-on-year.

Undervalued

The company’s latest PE is -16.19, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 193.26M shares, increasing 0.14% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 671.00 shares of this stock.

Analyst Rating

Based on 22 analysts

Buy

Current Rating

92.926

Target Price

+45.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of BridgeBio Pharma Inc is 8.41, ranking 70 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 120.70M, representing a year-over-year increase of 4318.01%, while its net profit experienced a year-over-year increase of 12.78%.

Score

Industry at a Glance

Previous score

8.41

Change

0



Financials

6.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of BridgeBio Pharma Inc is 6.77, ranking 114 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -16.19, which is -86.43% below the recent high of -2.20 and -17.43% above the recent low of -19.01.

Score

Industry at a Glance

Previous score

6.77

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 33/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of BridgeBio Pharma Inc is 8.55, ranking 29 out of 159 in the Pharmaceuticals industry. The average price target is 82.00, with a high of 110.00 and a low of 42.21.

Score

Industry at a Glance

Previous score

8.55

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of BridgeBio Pharma Inc is 7.18, ranking 75 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 78.64 and the support level at 60.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.75

Change

0.43

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of BridgeBio Pharma Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 104.83%, representing a quarter-over-quarter decrease of 2.22%. The largest institutional shareholder is The Vanguard, holding a total of 16.83M shares, representing 8.73% of shares outstanding, with 11.50% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

16.80M

+2.09%

Viking Global Investors LP

Star Investors

15.89M

-0.53%

Kohlberg Kravis Roberts & Co. L.P.

13.26M

--

BlackRock Institutional Trust Company, N.A.

11.92M

+0.24%

Janus Henderson Investors

8.74M

-5.77%

Farallon Capital Management, L.L.C.

8.19M

+3.70%

Kumar (Neil)

6.17M

--

Aisling Capital Management LP

6.09M

+0.35%

State Street Investment Management (US)

5.61M

-4.92%

Two Sigma Investments, LP

3.99M

-0.78%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BridgeBio Pharma Inc is 6.86, ranking 46 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.13. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. BridgeBio Pharma Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

BridgeBio Pharma Inc

BBIO

7.95 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment